To the full analysis
Jazz Pharmaceuticals stock: valuation and P/E
JAZZJazz Pharmaceuticals trades at a P/E of 75.5 (Biotechnology median 21.7, own median of recent years 16.6).
Daily figure as of 13 Nov 2026
P/E
75.5
earnings collapsed, on expected earnings 9.6
P/S
3.3
P/B
3.71
PEG
3.45
P/E on expected earnings
The forward P/E of 9.6 divides the price by the earnings per share that 11 analysts expect on average for the next twelve months: $25.05. The twelve months are made up pro rata of the estimates for fiscal 2026 and 2027. The P/E of 75.5, by contrast, uses reported earnings for the last twelve months.
9.6
P/E on fiscal 2026
16.1
on estimated fiscal 2026 earnings ($14.98 per share)
P/E on fiscal 2027
9
on estimated fiscal 2027 earnings ($26.61 per share)
Analysts mostly estimate adjusted earnings, excluding amortization of acquisitions and other one-off items. The estimates change all the time; they are no promise and no price target.
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
75.5
Median of prior years
16.6
Reading
pricier than usual
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2016 | 16.6 |
| 2017 | 16.6 |
| 2018 | 16.6 |
| 2019 | 16.2 |
| 2020 | 38.6 |
| 2023 | 18.8 |
| 2024 | 13.6 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.